A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: Chiauranib|DRUG: capecitabine
Sponsor: Chipscreen Biosciences, Ltd.